Megan Meyer Hanner, DO
Family Medicine · Newcastle, OKNPI 1801090717
Payments from drug & device makers
Across 132 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$322
- Lilly USA, LLC$306
- AbbVie$276
- Medtronic$249
- Novo Nordisk$226
- GSK$166
- plus $762 from 20 others
What the payments were for
- Food & beverage$2,307100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $322 |
| Lilly USA, LLC | 20 | $306 |
| AbbVie(2 entities) | 12 | $276 |
| Medtronic | 12 | $249 |
| Novo Nordisk | 13 | $226 |
| GSK | 10 | $166 |
| AstraZeneca | 9 | $142 |
| Boehringer Ingelheim | 5 | $83 |
| Exact Sciences | 5 | $79 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Merck | 3 | $46 |
| Dexcom, Inc. | 3 | $46 |
| Astellas Pharma US Inc | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Abbott | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 2 | $22 |
| Insulet Corporation | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Tonix Medicines, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,307 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $142,096 |
| JardianceEmpagliflozin | 68 | $82,323 |
| EliquisApixaban | 47 | $57,572 |
| MounjaroTirzepatide | 41 | $49,337 |
| JanuviaSitagliptin Phosphate | 28 | $37,459 |
| TrulicityDulaglutide | 22 | $32,133 |
| XareltoRivaroxaban | 14 | $25,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,066 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $21,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $18,326 |
| WegovySemaglutide | 11 | $16,601 |
| FarxigaDapagliflozin Propanediol | 15 | $14,663 |
| Spiriva RespimatTiotropium Bromide | 19 | $14,083 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,361 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $226 | $158,69896 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $83 | $102,08598 claims |
| Lilly USA, LLCMounjaro, Trulicity | $306 | $81,47163 claims |
| PfizerEliquis | $322 | $57,57247 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $142 | $38,85748 claims |
| MerckJanuvia | $46 | $37,45928 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $166 | $31,08242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Newcastle
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.